

# Arlene Chan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8203177/publications.pdf>

Version: 2024-02-01

50  
papers

7,478  
citations

471061

17  
h-index

214527

47  
g-index

51  
all docs

51  
docs citations

51  
times ranked

8154  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 201-208.	0.7	2
2	Drug induced vitiligo-like depigmentation from a CDK 4/6 inhibitor. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	0.7	9
3	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 106-115.	3.2	18
4	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	0.8	88
5	Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR <sup>±</sup> HER2 <sup>±</sup> Advanced Breast Cancer in the MONALEESA-3 Trial. <i>Clinical Breast Cancer</i> , 2022, 22, 326-335.	1.1	2
6	Code of practice needed for samples donated by trial participants. <i>Lancet Oncology, The</i> , 2022, 23, e89-e90.	5.1	4
7	Male Breast Cancer in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e57-e62.	0.7	8
8	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. <i>Clinical Breast Cancer</i> , 2021, 21, 80-91.e7.	1.1	140
9	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology, The</i> , 2021, 22, 212-222.	5.1	169
10	Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer. <i>Advances in Therapy</i> , 2021, 38, 4569-4580.	1.3	7
11	BreastSurgANZ members recommendations for adjuvant systemic treatment and patient compliance in Australian breast cancer patients. <i>ANZ Journal of Surgery</i> , 2021, 91, 2418-2424.	0.3	0
12	Psychosocial consequences in offspring of women with breast cancer. <i>Psycho-Oncology</i> , 2020, 29, 517-524.	1.0	10
13	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 60-72.	5.1	161
14	A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5310-5319.	3.2	102
15	Pigment Epithelium-Derived Factor and Sex Hormone-Responsive Cancers. <i>Cancers</i> , 2020, 12, 3483.	1.7	10
16	Adjuvant denosumab in early breast cancer – Authors' reply. <i>Lancet Oncology, The</i> , 2020, 21, e125.	5.1	2
17	Pigment epithelium-derived factor regulation of neuronal and stem cell fate. <i>Experimental Cell Research</i> , 2020, 389, 111891.	1.2	19
18	Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarchHER): a randomised, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2020, 21, 763-775.	5.1	144

#	ARTICLE	IF	CITATIONS
19	Compliance with multidisciplinary team meeting management recommendations. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 337-342.	0.7	12
20	Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. <i>Future Oncology</i> , 2019, 15, 2489-2501.	1.1	8
21	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019, 21, 39.	2.2	17
22	The role of pigment epithelium-derived factor in protecting against cellular stress. <i>Free Radical Research</i> , 2019, 53, 1166-1180.	1.5	23
23	Breast cancer bone metastases: pathogenesis and therapeutic targets. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 96, 63-78.	1.2	133
24	Efficacy of scalp cooling in reducing alopecia in early breast cancer patients receiving contemporary chemotherapy regimens. <i>Breast</i> , 2018, 41, 127-132.	0.9	15
25	A review of the importance of immune responses in luminal B breast cancer. <i>Oncolmmunology</i> , 2017, 6, e1282590.	2.1	5
26	TILs in metastatic breast cancer—no surprises, but more questions. <i>Lancet Oncology, The</i> , 2017, 18, 5-6.	5.1	4
27	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1688-1700.	5.1	451
28	Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study). <i>Supportive Care in Cancer</i> , 2017, 25, 3785-3791.	1.0	6
29	Trastuzumab biosimilar in early breast cancer setting: will there be direct patient benefits?. <i>Chinese Clinical Oncology</i> , 2017, 6, 55-55.	0.4	0
30	Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 339-350.	1.4	30
31	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1738-1748.	13.9	1,390
32	Neratinib after trastuzumab in patients with HER2-positive breast cancer — Author's reply. <i>Lancet Oncology, The</i> , 2016, 17, e176-e177.	5.1	12
33	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2016, 17, 367-377.	5.1	444
34	Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 368-375.	0.7	5
35	Utilisation of primary and secondary G-CSF prophylaxis enables maintenance of optimal dose delivery of standard adjuvant chemotherapy for early breast cancer: An analysis of 1655 patients. <i>Breast</i> , 2014, 23, 676-682.	0.9	9
36	Three-arm randomized phase II study evaluating oral vinorelbine plus capecitabine versus paclitaxel plus gemcitabine versus docetaxel plus gemcitabine as first-line chemotherapy in patients with metastatic breast cancer: Final results (NorCap-CA223 trial).. <i>Journal of Clinical Oncology</i> , 2014, 32, 1044-1044.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Developing and evaluation of a new clinicopathologic response index after neoadjuvant chemotherapy as a predictor of clinical outcomes in locally advanced breast cancers.. Journal of Clinical Oncology, 2014, 32, 1083-1083.	0.8	0
38	Prevalence of Excessive Tearing in Women With Early Breast Cancer Receiving Adjuvant Docetaxel-Based Chemotherapy. Journal of Clinical Oncology, 2013, 31, 2123-2127.	0.8	20
39	A multicenter audit of the incidence of febrile neutropenia and neutropenia associated with docetaxel and cyclophosphamide (TC) chemotherapy for early breast cancer.. Journal of Clinical Oncology, 2013, 31, 1079-1079.	0.8	3
40	Lack of efficacy of adjuvant lapatinib in HER2-negative breast cancer (HER2-ve BC): Analysis of patients in the TEACH trial.. Journal of Clinical Oncology, 2013, 31, 628-628.	0.8	1
41	Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.. Journal of Clinical Oncology, 2013, 31, TPS662-TPS662.	0.8	0
42	Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. Anticancer Research, 2013, 33, 2657-64.	0.5	5
43	A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease. BMC Cancer, 2012, 12, 555.	1.1	21
44	Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Critical Reviews in Oncology/Hematology, 2012, 81, 136-150.	2.0	14
45	Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancer. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 62-70.	0.7	2
46	Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine, 2011, 365, 1273-1283.	13.9	2,254
47	Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRC-005 Trial. Journal of Clinical Oncology, 2011, 29, 3877-3884.	0.8	135
48	Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2010, 28, 3239-3247.	0.8	812
49	A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Research and Treatment, 2008, 112, 533-543.	1.1	732
50	Subxiphoid partial pericardiectomy with or without sclerosant instillation in the treatment of symptomatic pericardial effusions in patients with malignancy. Cancer, 1991, 68, 1021-1025.	2.0	16